Biogen and Eisai’s monoclonal antibody drugs for Alzheimer’s — Aduhelm (now off the market) and Leqembi (fully approved by the FDA in 2023) —…
Biogen renounced ownership of their controversial anti-Alzheimer’s drug Aduhelm after years of dismal sales. The company is also halting an ongoing clinical trial set…
The process of finding new treatments for Alzheimer’s disease is one of trial and error — and every “failed” trial generates invaluable new data…
On July 6, 2023, the U.S. Food and Drug Administration fully approved the Alzheimer’s drug Leqembi (generic name lecanemab), a monoclonal antibody drug for…
I’ve always been a bit of a technology geek. I still have a few memories of sitting at my desk at the ACLU’s Washington…
As the proportion of older people in the population around the world increases, the prevalence of dementia will increase in turn. By 2030, it…
A few years ago, I listened to my doctors and grudgingly scheduled myself a colonoscopy – one of the most dreaded parts of hitting…
Alzheimer’s disease is responsible for 60 to 80 percent of all cases of dementia, and to date, most dementia research and treatments have focused…
UPDATE: 3 March 2024, 8:14 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
It was 7:20 a.m. and Joel Braunstein, co-founder and CEO of C2N Diagnostics, was about to start his second meeting of the day. C2N…
Alzheimer’s disease affects one in every three people over the age of 85, and the scale of the epidemic is only worsening. While there…
A new generation of Alzheimer’s treatments — groundbreaking, disease-modifying monoclonal antibody drugs — is on the rise, and two so far have hit the…
In January of 2023, the Food and Drug Administration approved the second anti-amyloid therapy for Alzheimer’s disease, Leqembi (generic name lecanemab). A new Alzheimer’s…
This article is part of the series Diversity & Dementia, produced by Being Patient with support provided by Eisai. Some of the United States’s most widespread…
I’m writing from Amsterdam, where this past week, the Being Patient editorial team has been reporting on the biggest news from the Alzheimer’s Association…